ELTX · Elicio Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Yekaterina Chudnovsky Director | ▼ Sell | Other | 5,416,212 Shares held | 3/5/2025 | View profile |
| EISA-ABC LLC 10% Owner | ▼ Sell | Other | 2,740,978 Shares held | 8/31/2021 | View profile |
| Goldberg Itzhak See Remarks | ▼ Sell | Tax Withholding | 1,687,986 Shares held | 7/1/2022 | View profile |
| Jay Venkatesan Director | ▼ Sell | Other | 179,581 Shares held | 11/26/2024 | View profile |
| Robert Connelly CEO, President and Director | ▲ Buy | Grant | 120,570 Shares held | 2/2/2026 | View profile |
| Christopher Haqq See Remarks | ▲ Buy | Grant | 57,381 Shares held | 2/2/2026 | View profile |
| Neylan John F. See Remarks | ▼ Sell | Open Market | 35,136 Shares held | 12/20/2021 | View profile |
| Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC | ▼ Sell | Open Market | 30,399 Shares held | 12/14/2021 | View profile |
| Preetam Shah See Remarks | ▲ Buy | Grant | 24,000 Shares held | 2/2/2026 | View profile |
| Peter DeMuth Chief Scientific Officer | ▲ Buy | Grant | 21,543 Shares held | 2/2/2026 | View profile |
| Nissenson Allen Director | ▲ Buy | Open Market | 9,383 Shares held | 5/20/2022 | View profile |
| CURHAN GREGORY S See Remarks | ▲ Buy | Open Market | 4,000 Shares held | 12/15/2021 | View profile |
Transaction History
| Robert Connelly | ▲ Buy | Grant | 73,600 | $0 | 2/2/2026 |
| Preetam Shah | ▲ Buy | Grant | 24,000 | $0 | 2/2/2026 |
| Peter DeMuth | ▲ Buy | Grant | 20,800 | $0 | 2/2/2026 |
| Christopher Haqq | ▲ Buy | Grant | 25,400 | $0 | 2/2/2026 |
| Peter DeMuth | ▲ Buy | Option Exercise | 362 | $2K | 12/9/2025 |
| Yekaterina Chudnovsky | ▼ Sell | Other | 3,500,573 | $20.3M | 3/5/2025 |
| Peter DeMuth | ▲ Buy | Option Exercise | 381 | $2K | 12/16/2024 |
| Jay Venkatesan | ▼ Sell | Other | 50,000 | $500 | 11/26/2024 |
| Yekaterina Chudnovsky | ▲ Buy | Open Market | 1,213,000 | $7.0M | 12/22/2023 |
| Goldberg Itzhak | ▼ Sell | Tax Withholding | 32,082 | $36K | 7/1/2022 |
| Jay Venkatesan | ▲ Buy | Open Market | 11,313 | $14K | 5/25/2022 |
| Jay Venkatesan | ▲ Buy | Open Market | 32,200 | $40K | 5/24/2022 |
| Jay Venkatesan | ▲ Buy | Open Market | 50,000 | $62K | 5/20/2022 |
| Nissenson Allen | ▲ Buy | Open Market | 2,037 | $2K | 5/20/2022 |
| Nissenson Allen | ▲ Buy | Open Market | 7,346 | $9K | 5/19/2022 |
| Jay Venkatesan | ▲ Buy | Open Market | 210,337 | $560K | 12/28/2021 |
| Jay Venkatesan | ▲ Buy | Open Market | 66,907 | $171K | 12/27/2021 |
| Jay Venkatesan | ▲ Buy | Open Market | 3,527 | $9K | 12/20/2021 |
| Neylan John F. | ▼ Sell | Open Market | 358 | $938 | 12/20/2021 |
| Jay Venkatesan | ▲ Buy | Open Market | 13,742 | $35K | 12/17/2021 |
| Jay Venkatesan | ▲ Buy | Open Market | 27,883 | $71K | 12/16/2021 |
| Jay Venkatesan | ▲ Buy | Open Market | 77,604 | $187K | 12/15/2021 |
| CURHAN GREGORY S | ▲ Buy | Open Market | 4,000 | $9K | 12/15/2021 |
| Rhodes Jennifer J | ▼ Sell | Open Market | 451 | $1K | 12/14/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 32,118 | $108K | 12/6/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 40,215 | $136K | 12/3/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 38,800 | $136K | 12/2/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 38,867 | $138K | 12/1/2021 |
| Neylan John F. | ▼ Sell | Open Market | 374 | $2K | 11/18/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 38,495 | $164K | 11/16/2021 |
| Goldberg Itzhak | ▼ Sell | Open Market | 111,505 | $465K | 11/15/2021 |
| Rhodes Jennifer J | ▼ Sell | Open Market | 433 | $2K | 11/15/2021 |
| Neylan John F. | ▼ Sell | Open Market | 373 | $3K | 10/18/2021 |
| Rhodes Jennifer J | ▼ Sell | Open Market | 430 | $4K | 10/14/2021 |
| Neylan John F. | ▼ Sell | Open Market | 376 | $4K | 9/20/2021 |
| Rhodes Jennifer J | ▼ Sell | Open Market | 430 | $5K | 9/14/2021 |
| EISA-ABC LLC | ▼ Sell | Other | 913,659 | $0 | 8/31/2021 |
| Neylan John F. | ▼ Sell | Open Market | 381 | $3K | 8/18/2021 |
| Rhodes Jennifer J | ▼ Sell | Open Market | 445 | $5K | 8/16/2021 |
| Jay Venkatesan | ▼ Sell | Tax Withholding | 41,091 | $566K | 6/24/2021 |
| Goldberg Itzhak | ▼ Sell | Tax Withholding | 47,410 | $653K | 6/24/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target
Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.